share_log

Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Resverlogix 發表了 Apabetalone 治療第三常見的肌肉萎縮症 FSHD 的潛力
newsfile ·  2023/10/04 19:12

Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells" in the journal Biomedicines.

加拿大阿爾伯塔省卡爾加裡-(Newsfile Corp.-2023年10月4日)-Resverlogix Corp.(多倫多證券交易所股票代碼:RVX)(以下簡稱Resverlogix)今天宣佈發表一篇同行評議的文章,題為臨床分期選擇性BET抑制劑阿帕貝酮對原代人FSHD肌細胞DUX4靶基因表達的影響“發表在《生物醫學》雜誌上。

"The beneficial effect of apabetalone highlighted in these models of facioscapulohumeral muscular dystrophy in combination with the impressive clinical and safety data in metabolic diseases, present further evidence to support apabetalone's potential benefit in the treatment of patients with this disease," said Donald McCaffrey, President and CEO at Resverlogix. "This exciting program will be added to a growing list of our compassionate use efforts that include post COVID-19 conditions, vascular dementia and chronic kidney disease, in addition to our upcoming core program Phase 3 clinical trial, BETonMACE2."

Resverlogix公司首席執行官兼首席執行官唐納德·麥卡弗裡說:“在這些面肩肩周肌營養不良模型中,阿帕貝酮的有益作用得到了強調,再加上代謝性疾病令人印象深刻的臨床和安全性數據,進一步的證據支持了阿帕貝酮在治療這種疾病患者中的潛在益處。除了我們即將進行的核心專案第三階段臨床試驗BETonMACE2外,這一令人興奮的計劃將被添加到我們越來越多的同情使用努力清單中,這些努力包括新冠肺炎後疾病、血管性痴獃和慢性腎臟疾病。“

The article is published online HERE.

這篇文章在這裡在線發表。

Publication Highlights Include:

出版物亮點包括:

  • Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent muscular dystrophies, affecting hundreds of thousands of people worldwide, and there are currently no approved therapeutics.
  • The disease is caused by the inappropriate expression of a specific protein, double homeobox 4 (DUX4) in patient's muscle cells.
  • DUX4 activation leads to cell death, inflammation, atrophy, and loss of muscle function.
  • Cultured muscle cells from FSHD patients were used to evaluate the potential of apabetalone to counter the negative effects of DUX4 activation.
  • Apabetalone treatment inhibited DUX4 activity and reversed its hallmark gene expression in these cells.
  • Treatment with apabetalone also did not negatively affect the differentiation or viability of the muscle cells, important indicators of the drug's safety.
  • 面肩肱骨肌營養不良症(FSHD)是最常見的肌營養不良症之一,全世界有數十萬人受到影響,目前還沒有得到批准的治療方法。
  • 這種疾病是由患者肌肉細胞中一種特殊的蛋白質雙同源盒4(DUX4)的不適當表達引起的。
  • DUX4激活會導致細胞死亡、炎症、萎縮和肌肉功能喪失。
  • 培養的FSHD患者的肌細胞被用來評估阿帕貝酮對抗DUX4激活的負面影響的潛力。
  • 阿帕貝酮可抑制DUX4的活性,並逆轉其標誌性基因的表達。
  • 阿帕貝酮的治療也沒有對肌肉細胞的分化或活性產生負面影響,這是該藥物安全性的重要指標。

"Currently available treatment options for FSHD lessen the burden of symptoms, but do nothing to address the disease's root cause," said Dr. Ewelina Kulikowski, Chief Scientific Officer at Resverlogix. "By directly inhibiting DUX4 activity in muscle cells, apabetalone has the potential to significantly improve the lives of FSHD patients."

Resverlogix首席科學官Ewell ina Kulikowski博士說:“目前可用的FSHD治療方案減輕了癥狀的負擔,但對解決疾病的根本原因毫無作用。”通過直接抑制肌肉細胞中的DUX4活性,阿帕貝酮有可能顯著改善FSHD患者的生活。

About Apabetalone

關於阿帕貝酮

Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes.

Apabetone(RVX-208)是一種一流的小分子候選藥物,具有表觀遺傳作用機制。它是一種BD2(溴域)選擇性BET(溴域和末端外)抑制劑,通過調節致病基因的表達來預防和治療疾病。

Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes representing a new way to treat chronic disease. Apabetalone is the only drug of its class that is well tolerated for chronic administration, with an established safety record in human clinical trials, including over 4200 patient-years of safety data across ten trials.

由於BET蛋白在人體中的廣泛作用,安培酮可以同時靶向多種與疾病相關的生物學過程,為治療慢性病提供了一種新的方法。Apabetone是同類藥物中唯一對長期給藥耐受性良好的藥物,在人體臨床試驗中有既定的安全記錄,包括10次試驗中超過4200名患者的安全數據。

Cardiology:

心臟病學:

Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food & Drug Administration for a major cardiovascular indication following the ground-breaking findings from its Phase 3 study, BETonMACE. Data from this trial showed apabetalone may prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.

Apabetone是第一種獲得美國食品和藥物管理局(FDA)指定的主要心血管適應症的突破療法,此前其3期研究BETonMACE取得了突破性發現。這項試驗的數據顯示,阿帕貝特可以預防同時患有2型糖尿病的高危心血管疾病患者的主要不良心臟事件。

About Resverlogix

關於Resverlogix

Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix成立於2001年,是一家總部設在卡爾加裡的晚期生物技術公司,是表觀遺傳學領域的世界領先者,目標是為慢性病患者開發一流的治療方法。

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.

Resverlogix正在開發一種新的表觀遺傳療法,旨在調節致病基因的表達。我們的目標是通過將因心血管疾病等嚴重疾病而改變的生物功能恢復到更健康的狀態來改善患者的生活。

The company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post COVID-19 conditions.

該公司的臨床計劃重點是評估治療心血管疾病和相關合並症以及新冠肺炎後遺症的主要表觀遺傳學候選藥物阿帕貝酮。

Resverlogix has partnered with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Resverlogix與全球生命科學行業下一代商業服務的先驅EVERSANA公司建立了合作夥伴關係,以支持用於心血管疾病、新冠肺炎後疾病和肺動脈高壓的阿帕貝酮在加拿大和美國的快速商業化。

Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).

Resverlogix普通股在多倫多證券交易所(多倫多證券交易所市場代碼:RVX)交易。

Follow us:

跟我們來:

  • X.com (formerly Twitter): @Resverlogix_RVX
  • LinkedIn:
  • X.com(前身為Twitter):@Resverlogix_rvx
  • LinkedIn:

Forward-Looking Statements:

前瞻性陳述:

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with facioscapulohumeral muscular dystrophy, cardiovascular disease, chronic kidney disease, vascular dementia, COVID-19, post COVID-19 conditions, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

本新聞稿可能包含某些根據適用的加拿大證券法定義的不基於歷史事實的前瞻性資訊,包括但不限於包含“相信”、“預期”、“計劃”、“打算”、“將”、“應該”、“預期”、“繼續”、“估計”、“預測”以及其他類似表述的陳述。特別是,本新聞稿包括與apabetone在治療面肩肩周肌營養不良、心血管疾病、慢性腎臟疾病、血管性痴獃、新冠肺炎、新冠肺炎後疾病、相關合並症和其他慢性病患者的潛在作用有關的前瞻性資訊。我們的實際結果、事件或發展可能與這些前瞻性陳述中明示或暗示的結果、事件或發展大不相同。我們不能保證任何事件或預期都會發生或實現。就其性質而言,前瞻性陳述受許多假設和風險因素的影響,包括在我們的年度資訊表格和最新的MD&A中討論的那些,這些陳述通過引用併入本文,並可通過SEDAR獲得,網址:。本新聞稿中包含的前瞻性陳述明確地受到這一警示聲明的限制,並且是在本新聞稿發佈之日作出的。除法律要求外,公司沒有任何意圖,也沒有義務或責任更新或修改任何前瞻性陳述,無論是由於新資訊、未來事件或其他原因。

For further information please contact:

欲瞭解更多資訊,請聯繫:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252

投資者關係
電子郵件:ir@resverlogix.com
電話:403-254-9252

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論